Results 131 to 140 of about 13,011 (272)

Comparative Efficacy and Safety Between Deferiprone and Deferasirox with Special Reference to Serum Ferritin Level and Cardiac Function in Bengali β-Thalassemia Major Children

, 2021
Isita Tripathy, Amrita Panja, Tuphan Kanti Dolai, Asim Kumar Mallick   +3 more
openalex   +2 more sources

Transparency and Access to Full Information for the Fatal or Serious Toxicity Risks, Low Efficacy and High Price of Deferasirox, Could Increase the Prospect of Improved Iron Chelation Therapy Worldwide [PDF]

, 2008
George J. Kontoghiorghes
openalex   +1 more source

Management of iron overload in myelodysplastic syndromes: combined deferasirox and deferoxamine in a patient with liver disease [PDF]

, 2016
AVILIA, SIMONA, CATALANO, LUCIO, CERCHIONE, CLAUDIO, Cerciello, Giuseppe, DELLA PEPA, ROBERTA, Pane, Fabrizio, PICARDI, MARCO, PUGLIESE, NOVELLA   +7 more
core   +1 more source

Iron‐chelating therapy with deferasirox in transfusion‐dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study [PDF]

, 2017
Pellegrino Musto, Luca Maurillo, Vittorio Simeon, Antonella Poloni, Carlo Finelli, Enrico Balleari, Alessandra Ricco, Flavia Rivellini, Agostino Cortelezzi, Giuseppe Tarantini, Oreste Villani, Giovanna Mansueto, Maria R. Milella, Daniele Scapicchio, Gioacchino Marziano, Massimo Breccia, Pasquale Niscola, Alessandro Sanna, Cristina Clissa, Maria Teresa Voso, Susanna Fenu, Adriano Venditti, Valeria Santini, Emanuele Angelucci, Alessandro Levis   +24 more
openalex   +1 more source

What is known about deferasirox chelation therapy in pediatric HSCT recipients: two case reports of metabolic acidosis

Therapeutics and Clinical Risk Management, 2018
Carmen Fucile,1 Francesca Mattioli,1 Valeria Marini,1 Massimo Gregori,2 Aurelio Sonzogni,3 Antonietta Martelli,1 Natalia Maximova4 1Pharmacology and Toxicology Unit, University of Genoa, Genoa, Italy; 2Department of Pediatric Radiology, Institute for ...
Fucile C, Mattioli F, Marini V, Gregori M, Sonzogni A, Martelli A, Maximova N   +6 more
doaj  

Deferasirox (ExJade): A Fluorescent Pro-Chelator Active Against Antibiotic Resistant Bacteria [PDF]

, 2020
Adam C. Sedgwick, Kai‐Cheng Yan, Daniel N. Mangel, Ying Shang, Axel Steinbrueck, Hai‐Hao Han, James T. Brewster, Xi‐Le Hu, Dylan W. Snelson, Vincent M. Lynch, He Tian, Xiaopeng He, Jonathan L. Sessler   +12 more
openalex   +1 more source

Successful Deferasirox Rechallenge and Treating Through Reaction in a Patient with Challenge-Proven Mild Immediate Reaction: A Case Report

Journal of Asthma and Allergy, 2020
Mongkhon Sompornrattanaphan,1 Thanachit Krikeerati,1,2 Chamard Wongsa,1 Torpong Thongngarm,1 Kittika Yampayon3 1Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok ...
Sompornrattanaphan M, Krikeerati T, Wongsa C, Thongngarm T, Yampayon K   +4 more
doaj  

Federated Tensor Factorization for Computational Phenotyping

, 2017
Tensor factorization models offer an effective approach to convert massive electronic health records into meaningful clinical concepts (phenotypes) for data analysis. These models need a large amount of diverse samples to avoid population bias.
Jiang, Xiaoqian, Kim, Yejin, Sun, Jimeng, Yu, Hwanjo   +3 more
core   +1 more source

Management of Oral Iron Chelator Deferasirox for Transfusion-Dependent Patients with Hematological Disorders: 2-year Experience at a Single Institution in Japan

, 2011
Michihide Tokuhira, M. Sagawa, Reiko Watanabe, Tomoe Nemoto, Takeshi Tomikawa, Shigehisa Mori, Masahiro Kizaki   +6 more
openalex   +2 more sources

Iron chelator deferasirox inhibits NF-κB activity in hepatoma cells and changes sorafenib-induced programmed cell deaths.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022
W. Jomen, T. Ohtake, Takayuki Akita, Daisuke Suto, Hideki Yagi, Y. Osawa, Y. Kohgo   +6 more
semanticscholar   +1 more source